BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24649955)

  • 1. Potential strategies for increasing drug-discovery productivity.
    Cumming JG; Finlay MR; Giordanetto F; Hemmerling M; Lister T; Sanganee H; Waring MJ
    Future Med Chem; 2014 Apr; 6(5):515-27. PubMed ID: 24649955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benefits of constructing leads from fragment hits.
    Foloppe N
    Future Med Chem; 2011 Jul; 3(9):1111-5. PubMed ID: 21806375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.
    Kell DB
    FEBS J; 2013 Dec; 280(23):5957-80. PubMed ID: 23552054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery.
    Fang Y
    Expert Opin Drug Discov; 2015 Apr; 10(4):331-43. PubMed ID: 25727255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in the discovery and development of negative allosteric modulators of mGluR5.
    Lindsley CW; Emmitte KA
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):446-57. PubMed ID: 19562641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular library design using multi-objective optimization methods.
    Nicolaou CA; Kannas CC
    Methods Mol Biol; 2011; 685():53-69. PubMed ID: 20981518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charting, navigating, and populating natural product chemical space for drug discovery.
    Lachance H; Wetzel S; Kumar K; Waldmann H
    J Med Chem; 2012 Jul; 55(13):5989-6001. PubMed ID: 22537178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing zebrafish chemical screens.
    Peterson RT; Fishman MC
    Methods Cell Biol; 2011; 105():525-41. PubMed ID: 21951546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicinal chemistry inspired fragment-based drug discovery.
    Lanter J; Zhang X; Sui Z
    Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Historical overview of chemical library design.
    Dolle RE
    Methods Mol Biol; 2011; 685():3-25. PubMed ID: 20981516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
    Campbell JB
    IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.